FDA grants Fast-Track designation to GW's Sativex pain treatment

|About: GW Pharmaceuticals plc (GWPH)|By:, SA News Editor

GW Pharmaceuticals' (GWPH) Sativex, which is used to treat pain in patients with advanced cancer, has received Fast-Track designation from the FDA.

As a cannabinoid medicine, Sativex is the only non-opioid treatment in Phase 3 development for patients who don't respond to, or experience negative side effects, with opioid medications, GW says.

Shares are +6.8%. (PR)